Vénéreau, E., Ceriotti, C. & Bianchi, M. E. DAMPs from cell death to new life. Front. Immunol. 6, 422 (2015).
Chen, G. Y. & Nuñez, G. Sterile inflammation: sensing and reacting to damage. Nat. Rev. Immunol. 10, 826–837 (2010).
Chen, F. et al. DAMPs in immunosenescence and cancer. Semin. Cancer Biol. 106–107, 123–142 (2024).
Kono, H. & Rock, K. L. How dying cells alert the immune system to danger. Nat. Rev. Immunol. 8, 279–289 (2008).
Mogensen, T. H. Pathogen recognition and inflammatory signaling in innate immune defenses. Clin. Microbiol. Rev. 22, 240–273 (2009).
Kwak, M. S. et al. ROS anchor PAMPs-mediated extracellular HMGB1 self-association and its dimerization enhances pro-inflammatory signaling. Redox Biol. 80, 103521 (2025).
Huang, Y., Jiang, W. & Zhou, R. DAMP sensing and sterile inflammation: intracellular, intercellular and inter-organ pathways. Nat. Rev. Immunol. 24, 703–719 (2024).
Rock, K. L., Latz, E., Ontiveros, F. & Kono, H. The sterile inflammatory response. Annu. Rev. Immunol. 28, 321–342 (2010).
Kiriakidou, M. & Ching, C. L. Systemic lupus erythematosus. Ann. Intern. Med. 172, Itc81–itc96 (2020).
Hotamisligil, G. S. Inflammation and metabolic disorders. Nature 444, 860–867 (2006).
Castro-Gomez, S. & Heneka, M. T. Innate immune activation in neurodegenerative diseases. Immunity 57, 790–814 (2024).
Zitvogel, L., Kepp, O. & Kroemer, G. Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat. Rev. Clin. Oncol. 8, 151–160 (2011).
Lee, S. A., Kwak, M. S., Kim, S. & Shin, J. S. The role of high mobility group box 1 in innate immunity. Yonsei Med. J. 55, 1165–1176 (2014).
Kwak, M. S. et al. Immunological significance of HMGB1 post-translational modification and redox biology. Front. Immunol. 11, 1189 (2020).
Goodwin, G. H. & Johns, E. W. Isolation and characterisation of two calf-thymus chromatin non-histone proteins with high contents of acidic and basic amino acids. Eur. J. Biochem. 40, 215–219 (1973).
Wang, H. et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science 285, 248–251 (1999).
Scaffidi, P., Misteli, T. & Bianchi, M. E. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 418, 191–195 (2002).
Herb, M. & Schramm, M. Functions of ROS in macrophages and antimicrobial immunity. Antioxidants 10, 313 (2021).
Canton, M. et al. Reactive oxygen species in macrophages: sources and targets. Front. Immunol. 12, 734229 (2021).
Liu, J. et al. Reactive oxygen species (ROS) scavenging biomaterials for anti-inflammatory diseases: from mechanism to therapy. J. Hematol. Oncol. 16, 116 (2023).
Vlahopoulos, S., Boldogh, I., Casola, A. & Brasier, A. R. Nuclear factor-kappaB-dependent induction of interleukin-8 gene expression by tumor necrosis factor alpha: evidence for an antioxidant sensitive activating pathway distinct from nuclear translocation. Blood 94, 1878–1889 (1999).
Hedrick, E., Mohankumar, K., Lacey, A. & Safe, S. Inhibition of NR4A1 promotes ROS accumulation and IL24-Dependent growth arrest in Rhabdomyosarcoma. Mol. Cancer Res. 17, 2221–2232 (2019).
Thiele, G. M. et al. Malondialdehyde-acetaldehyde adducts and anti-malondialdehyde-acetaldehyde antibodies in rheumatoid arthritis. Arthritis Rheumatol. 67, 645–655 (2015).
Griess, B., Mir, S., Datta, K. & Teoh-Fitzgerald, M. Scavenging reactive oxygen species selectively inhibits M2 macrophage polarization and their pro-tumorigenic function in part, via Stat3 suppression. Free Radic. Biol. Med. 147, 48–60 (2020).
Li, J. et al. Structural basis for the proinflammatory cytokine activity of high mobility group box 1. Mol. Med. 9, 37–45 (2003).
Gong, W., Li, Y., Chao, F., Huang, G. & He, F. Amino acid residues 201–205 in C-terminal acidic tail region plays a crucial role in antibacterial activity of HMGB1. J. Biomed. Sci. 16, 83 (2009).
Stros, M. DNA bending by the chromosomal protein HMG1 and its high mobility group box domains. Effect of flanking sequences. J. Biol. Chem. 273, 10355–10361 (1998).
Stros, M. HMGB proteins: interactions with DNA and chromatin. Biochim. Biophys. Acta 1799, 101–113 (2010).
Sims, G. P., Rowe, D. C., Rietdijk, S. T., Herbst, R. & Coyle, A. J. HMGB1 and RAGE in inflammation and cancer. Annu. Rev. Immunol. 28, 367–388 (2010).
Youn, J. H., Oh, Y. J., Kim, E. S., Choi, J. E. & Shin, J. S. High mobility group box 1 protein binding to lipopolysaccharide facilitates transfer of lipopolysaccharide to CD14 and enhances lipopolysaccharide-mediated TNF-alpha production in human monocytes. J. Immunol. 180, 5067–5074 (2008).
Youn, J. H. et al. Identification of lipopolysaccharide-binding peptide regions within HMGB1 and their effects on subclinical endotoxemia in a mouse model. Eur. J. Immunol. 41, 2753–2762 (2011).
Kwak, M. S. et al. Peroxiredoxin-mediated disulfide bond formation is required for nucleocytoplasmic translocation and secretion of HMGB1 in response to inflammatory stimuli. Redox Biol. 24, 101203 (2019).
Yang, K. et al. Lactate promotes macrophage HMGB1 lactylation, acetylation, and exosomal release in polymicrobial sepsis. Cell Death Differ. 29, 133–146 (2022).
Yang, R. et al. Posttranslational S-nitrosylation modification regulates HMGB1 secretion and promotes its proinflammatory and neurodegenerative effects. Cell Rep. 40, 111330 (2022).
Youn, J. H. & Shin, J. S. Nucleocytoplasmic shuttling of HMGB1 is regulated by phosphorylation that redirects it toward secretion. J. Immunol. 177, 7889–7897 (2006).
Oh, Y. J. et al. HMGB1 is phosphorylated by classical protein kinase C and is secreted by a calcium-dependent mechanism. J. Immunol. 182, 5800–5809 (2009).
Oh, Y. J. et al. CKD712, (S)-1-(alpha-naphthylmethyl)-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline, inhibits the lipopolysaccharide-stimulated secretion of HMGB1 by inhibiting PI3K and classical protein kinase C. Int. Immunopharmacol. 11, 1160–1165 (2011).
Zhang, X. et al. Calcium/calmodulin-dependent protein kinase (CaMK) IV mediates nucleocytoplasmic shuttling and release of HMGB1 during lipopolysaccharide stimulation of macrophages. J. Immunol. 181, 5015–5023 (2008).
Bonaldi, T. et al. Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion. EMBO J. 22, 5551–5560 (2003).
Kim, Y. H. et al. N-linked glycosylation plays a crucial role in the secretion of HMGB1. J. Cell Sci. 129, 29–38 (2016).
Ito, I., Fukazawa, J. & Yoshida, M. Post-translational methylation of high mobility group box 1 (HMGB1) causes its cytoplasmic localization in neutrophils. J. Biol. Chem. 282, 16336–16344 (2007).
Ditsworth, D., Zong, W. X. & Thompson, C. B. Activation of poly(ADP)-ribose polymerase (PARP-1) induces release of the pro-inflammatory mediator HMGB1 from the nucleus. J. Biol. Chem. 282, 17845–17854 (2007).
Shin, J. et al. USP13 regulates HMGB1 stability and secretion through its deubiquitinase activity. Mol. Med. 28, 164 (2022).
Li, H. et al. Deubiquitylase USP12 induces pro-survival autophagy and bortezomib resistance in multiple myeloma by stabilizing HMGB1. Oncogene 41, 1298–1308 (2022).
Yao, W. et al. Epigenetic regulator KDM4D restricts tumorigenesis via modulating SYVN1/HMGB1 ubiquitination axis in esophageal squamous cell carcinoma. Front. Oncol. 11, 761346 (2021).
Du, J. et al. Ubiquitination of cytoplasmic HMGB1 by RNF186 regulates hepatic lipophagy in non-alcoholic fatty liver disease. Metabolism 152, 155769 (2024).
Kim, Y. H. et al. Secretory autophagy machinery and vesicular trafficking are involved in HMGB1 secretion. Autophagy 17, 2345–2362 (2021).
Pirani, E. et al. Tumor cells express and maintain HMGB1 in the reduced isoform to enhance CXCR4-mediated migration. Front. Immunol. 15, 1358800 (2024).
Kazama, H. et al. Induction of immunological tolerance by apoptotic cells requires caspase-dependent oxidation of high-mobility group box-1 protein. Immunity 29, 21–32 (2008).
Kwak, M. S. et al. Reactive oxygen species induce Cys106-mediated anti-parallel HMGB1 dimerization that protects against DNA damage. Redox Biol. 40, 101858 (2021).
Lee, J. J. et al. HMGB1 orchestrates STING-mediated senescence via TRIM30α modulation in cancer cells. Cell Death Discov. 7, 28 (2021).
Kang, R. et al. Metabolic regulation by HMGB1-mediated autophagy and mitophagy. Autophagy 7, 1256–1258 (2011).
Zhang, S. et al. Recombinant high-mobility group box 1 (rHMGB1) promotes NRF2-independent mitochondrial fusion through CXCR4/PSMB5-mediated Drp1 degradation in endothelial cells. Oxid. Med. Cell. Longev. 2021, 9993240 (2021).
Han, J. Y., Rhee, W. J. & Shin, J. S. Cytoplasmic HMGB1 promotes the activation of JAK2–STAT3 signaling and PD-L1 expression in breast cancer. Mol. Med. 31, 197 (2025).
Min, H. J. et al. Chaperone-like activity of high-mobility group box 1 protein and its role in reducing the formation of polyglutamine aggregates. J. Immunol. 190, 1797–1806 (2013).
Kwak, M. S. et al. HMGB1 binds to lipoteichoic acid and enhances TNF-α and IL-6 production through HMGB1-mediated transfer of lipoteichoic acid to CD14 and TLR2. J. Innate Immun. 7, 405–416 (2015).
Ved, R. et al. Disulfide HMGB1 acts via TLR2/4 receptors to reduce the numbers of oligodendrocyte progenitor cells after traumatic injury in vitro. Sci. Rep. 11, 6181 (2021).
Yang, H. et al. MD-2 is required for disulfide HMGB1-dependent TLR4 signaling. J. Exp. Med. 212, 5–14 (2015).
Das, N. et al. HMGB1 activates proinflammatory signaling via TLR5 leading to allodynia. Cell Rep. 17, 1128–1140 (2016).
Ge, X. et al. A protein complex of liver origin activates a pro-inflammatory program that drives hepatic and intestinal injury in alcohol-associated liver disease. Cell. Mol. Gastroenterol. Hepatol. 18, 101362 (2024).
Shin, J. W. et al. Propagation of senescent phenotypes by extracellular HMGB1 is dependent on its redox state. Metabolism 168, 156259 (2025).
García-Arnandis, I. et al. High mobility group box 1 potentiates the pro-inflammatory effects of interleukin-1β in osteoarthritic synoviocytes. Arthritis Res. Ther. 12, R165 (2010).
Schiraldi, M. et al. HMGB1 promotes recruitment of inflammatory cells to damaged tissues by forming a complex with CXCL12 and signaling via CXCR4. J. Exp. Med. 209, 551–563 (2012).
Yanai, H. et al. HMGB proteins function as universal sentinels for nucleic-acid-mediated innate immune responses. Nature 462, 99–103 (2009).
Mori, H. et al. Reduced-HMGB1 suppresses poly(I:C)-induced inflammation in keratinocytes. J. Dermatol. Sci. 90, 154–165 (2018).
Sosa, R. A. et al. Immune features of Disparate Liver transplant outcomes in female hispanics with nonalcoholic steatohepatitis. Transplant. Direct 9, e1550 (2023).
Terry, A. Q. et al. Disulfide-HMGB1 signals through TLR4 and TLR9 to induce inflammatory macrophages capable of innate-adaptive crosstalk in human liver transplantation. Am. J. Transplant. 23, 1858–1871 (2023).
Chiba, S. et al. Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1. Nat. Immunol. 13, 832–842 (2012).
Urbonaviciute, V. et al. Oxidation of the alarmin high-mobility group box 1 protein (HMGB1) during apoptosis. Autoimmunity 42, 305–307 (2009).
Yu, C. et al. Role of HMGB1 in TNF-α combined with Z-VAD-fmk-induced L929 cells necroptosis. Biochem. Genet. 60, 598–610 (2022).
Kaczmarek, A., Vandenabeele, P. & Krysko, D. V. Necroptosis: the release of damage-associated molecular patterns and its physiological relevance. Immunity 38, 209–223 (2013).
Thorburn, J. et al. Autophagy regulates selective HMGB1 release in tumor cells that are destined to die. Cell Death Differ. 16, 175–183 (2009).
Schiller, M. et al. During apoptosis HMGB1 is translocated into apoptotic cell-derived membranous vesicles. Autoimmunity 46, 342–346 (2013).
Wen, Q., Liu, J., Kang, R., Zhou, B. & Tang, D. The release and activity of HMGB1 in ferroptosis. Biochem. Biophys. Res. Commun. 510, 278–283 (2019).
Lu, B. et al. Novel role of PKR in inflammasome activation and HMGB1 release. Nature 488, 670–674 (2012).
Yang, H., Wang, H., Chavan, S. S. & Andersson, U. High mobility group box protein 1 (HMGB1): the prototypical endogenous danger molecule. Mol. Med. 21, S6–S12 (2015).
Murao, A., Aziz, M., Wang, H., Brenner, M. & Wang, P. Release mechanisms of major DAMPs. Apoptosis 26, 152–162 (2021).
Kwak, M. S. et al. SARS-CoV-2 infection induces HMGB1 secretion through post-translational modification and PANoptosis. Immune Netw. 23, e26 (2023).
Jung, S. F. et al. Direct interaction of HMGB1 with SARS-CoV-2 facilitates its infection via RAGE-dependent endocytosis. iScience 28, 113063 (2025).
Minsart, C. et al. New insights in acetaminophen toxicity: HMGB1 contributes by itself to amplify hepatocyte necrosis in vitro through the TLR4-TRIF–RIPK3 axis. Sci. Rep. 10, 5557 (2020).
Huebener, P. et al. The HMGB1/RAGE axis triggers neutrophil-mediated injury amplification following necrosis. J. Clin. Invest. 125, 539–550 (2015).
Meng, R. et al. High mobility group box 1 enables bacterial lipids to trigger receptor-interacting protein kinase 3 (RIPK3)-mediated necroptosis and apoptosis in mice. J. Biol. Chem. 294, 8872–8884 (2019).
Liu, Y. et al. Extracellular HMGB1 prevents necroptosis in acute myeloid leukemia cells. Biomed. Pharmacother. 112, 108714 (2019).
Davaanyam, D. et al. HMGB1 induces hepcidin upregulation in astrocytes and causes an acute iron surge and subsequent ferroptosis in the postischemic brain. Exp. Mol. Med. 55, 2402–2416 (2023).
Tang, D. et al. HMGB1 release and redox regulates autophagy and apoptosis in cancer cells. Oncogene 29, 5299–5310 (2010).
Deng, M. et al. The endotoxin delivery protein HMGB1 mediates caspase-11-dependent lethality in sepsis. Immunity 49, 740–753 (2018).
Shang, J. et al. HMGB1 mediates lipopolysaccharide-induced macrophage autophagy and pyroptosis. BMC Mol. Cell Biol. 24, 2 (2023).
Kim, S. Y. et al. High-mobility group box 1-induced complement activation causes sterile inflammation. Front. Immunol. 9, 705 (2018).
Tang, D. et al. Endogenous HMGB1 regulates autophagy. J. Cell Biol. 190, 881–892 (2010).
Lee, J. J., Park, I. H., Rhee, W. J., Kim, H. S. & Shin, J. S. HMGB1 modulates the balance between senescence and apoptosis in response to genotoxic stress. FASEB J. 33, 10942–10953 (2019).
Ferrara, M. et al. Oxidation of HMGB1 is a dynamically regulated process in physiological and pathological conditions. Front. Immunol. 11, 1122 (2020).
Aucott, H. et al. Neuroinflammation in response to intracerebral injections of different HMGB1 Redox Isoforms. J. Innate Immun. 10, 215–227 (2018).
Okuma, Y. et al. Anti-high mobility group box-1 antibody therapy for traumatic brain injury. Ann. Neurol. 72, 373–384 (2012).
Fu, L. et al. Therapeutic effects of anti-HMGB1 monoclonal antibody on pilocarpine-induced status epilepticus in mice. Sci. Rep. 7, 1179 (2017).
Fujita, K. et al. HMGB1, a pathogenic molecule that induces neurite degeneration via TLR4-MARCKS, is a potential therapeutic target for Alzheimer’s disease. Sci. Rep. 6, 31895 (2016).
Sasaki, T. et al. Anti-high mobility group box 1 antibody exerts neuroprotection in a rat model of Parkinson’s disease. Exp. Neurol. 275, 220–231 (2016).
Entezari, M. et al. Inhibition of extracellular HMGB1 attenuates hyperoxia-induced inflammatory acute lung injury. Redox Biol. 2, 314–322 (2014).
Yang, R., Tenhunen, J. & Tonnessen, T. I. HMGB1 and Histones play a significant role in inducing systemic inflammation and multiple organ dysfunctions in severe acute pancreatitis. Int. J. Inflam. 2017, 1817564 (2017).
Cecchinato, V. et al. Redox-mediated mechanisms Fuel Monocyte responses to CXCL12/HMGB1 in active rheumatoid arthritis. Front. Immunol. 9, 2118 (2018).
Maugeri, N. et al. Oxidative stress elicits platelet/leukocyte inflammatory interactions via HMGB1: a candidate for microvessel injury in sytemic sclerosis. Antioxid. Redox Signal. 20, 1060–1074 (2014).
Zong, M. et al. TLR4 as receptor for HMGB1 induced muscle dysfunction in myositis. Ann. Rheum. Dis. 72, 1390–1399 (2013).
Lundbäck, P. et al. Characterization of the inflammatory properties of actively released HMGB1 in juvenile idiopathic arthritis. Antioxid. Redox Signal. 24, 605–619 (2016).
Di Maggio, S. et al. Non-oxidizable HMGB1 induces cardiac fibroblasts migration via CXCR4 in a CXCL12-independent manner and worsens tissue remodeling after myocardial infarction. Biochim. Biophys. Acta Mol. Basis Dis. 1863, 2693–2704 (2017).
Sosa, R. A. et al. Disulfide high-mobility group box 1 drives Ischemia-Reperfusion injury in human liver transplantation. Hepatology 73, 1158–1175 (2021).
Wu, H. et al. HMGB1 contributes to kidney ischemia reperfusion injury. J. Am. Soc. Nephrol. 21, 1878–1890 (2010).
Wang, C. et al. Inhibiting HMGB1 reduces cerebral ischemia reperfusion injury in diabetic mice. Inflammation 39, 1862–1870 (2016).
Cai, J. et al. HMGB1-driven inflammation and intimal Hyperplasia after arterial injury involves cell-specific actions mediated by TLR4. Arterioscler. Thromb. Vasc. Biol. 35, 2579–2593 (2015).
Davaanyam, D., Seol, S. I., Oh, S. A., Lee, H. & Lee, J. K. Hepatocyte activation and liver injury following cerebral ischemia promote HMGB1-mediated hepcidin upregulation in hepatocytes and regulation of systemic iron levels. Exp. Mol. Med. 56, 2171–2183 (2024).
Stevens, N. E. et al. Therapeutic targeting of HMGB1 during experimental sepsis modulates the inflammatory cytokine profile to one associated with improved clinical outcomes. Sci. Rep. 7, 5850 (2017).
Abdulmahdi, W. et al. HMGB1 redox during sepsis. Redox Biol. 13, 600–607 (2017).
Hubert, P. et al. Extracellular HMGB1 blockade inhibits tumor growth through profoundly remodeling immune microenvironment and enhances checkpoint inhibitor-based immunotherapy. J. Immunother. Cancer 9, e001966 (2021).